newsfilter
← Latest News
GlobeNewswire·

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases

First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runwayTrading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc.